

## Freedom of Information Request: Our Reference CTMUHB\_37\_23

You asked:

**Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:-**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Apremilast**
- **Bimekizumab**
- **Brodalumab**
- **Certolizumab**
- **Dimethyl fumarate**
- **Etanercept - Enbrel**
- **Etanercept Biosimilar**
- **Guselkumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ixekizumab**
- **Risankizumab**
- **Secukinumab**
- **Tildrakizumab**
- **Ustekinumab**

Please see provided below a table populated with the data that Medicines Management are able to provide. The period relates to the last 3 months available which is 1<sup>st</sup> October 2022 to 31<sup>st</sup> December 2022.

The majority of CTMUHB patients that fall within the Merthyr & Cynon and Rhondda, Taff Ely Localities requiring treatment for some dermatological conditions with the medicines outlined in your request above, will be referred into the services of a neighbouring Health Board, Cardiff and Vale UHB. Hopefully, this will provide an explanation as to why our patient numbers are low for the medicines relating to your above enquiry.

<b>Medicine</b>	<b>Number of Patients</b>
Adalimumab - Humira	**
Adalimumab Biosimilar	37
Apremilast	70
Bimekizumab	10
Brodalumab	6
Certolizumab	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	**
Guselkumab	28
Infliximab - Remicade	0
Infliximab Biosimilar	**
Ixekizumab	17

Risankizumab	**
Secukinumab	**
Tildrakizumab	0
Ustekinumab	41

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Q2. How many patients were treated in the last 3 months by the Dermatology department for Hidradenitis Suppurativa (HS) ONLY with the following biologic drugs:-**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Secukinumab**
- **Ustekinumab**

Patient level details are not captured on our Medicines Management system. Therefore, we are unable to provide the number of patients treated for specific medical conditions.

The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

**Q3. How many patients were treated in the last 3 months by the Dermatology department for Psoriasis ONLY in the last three months with the following:-**

- **Ciclosporin**
- **Methotrexate - any form and strength**
- **Methotrexate injections 15mg and above**

Please see response to question 2.